Adlai Nortye (NASDAQ:ANL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Adlai Nortye (NASDAQ:ANL) to a hold rating in a research note issued to investors on Saturday.

Several other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. HC Wainwright raised shares of Adlai Nortye from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, February 13th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.00.

Adlai Nortye Price Performance

Shares of NASDAQ ANL opened at $8.91 on Friday. The stock has a 50 day moving average price of $5.93 and a 200 day moving average price of $3.10. Adlai Nortye has a 52 week low of $0.88 and a 52 week high of $12.09.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.